CDEK
← All drugs Report issue

erenumab

Trade name: aimovig

mAbapproved

Approved

May 17, 2018

Erenumab, sold under the brand name Aimovig, is a medication which blocks the calcitonin gene-related peptide receptor (CGRPR) for the prevention of migraine. It is administered by subcutaneous injection. — Wikipedia

Clinical trial activity

53 trials · 24 clinical orgs · 1 marketing orgs

Phase 1
9
Phase 2
26
Phase 3
10
Phase 4
17

Earliest trial started Mar 1, 2012 (NCT01688739)

Timeline

2010s

  1. Jan 1, 2012

    Amgen — Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2013

    Amgen — Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2015

    Amgen — Earliest Phase 3 Sponsor(trial)

  4. May 17, 2018

    Amgen — Earliest FDA Approval

  5. May 17, 2018

    Amgen — Marketing Organization

  6. May 17, 2018

    Amgen — NDA Organization

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedMay 17, 2018

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Parenteral
Multi-specific
No

Oral

No

Parenteral

Yes

Topical

No

First in class

Sources

Also known as

  • amg 334
  • erenumab-aooe

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05684692Phase 2Aug 31, 2023Department of Defense, Harvard University, Recordati
NCT05162027Phase 2Apr 30, 2022Amgen, University of Maryland
NCT05142228Phase 2Apr 30, 2022Amgen, University of Maryland
NCT05284019Phase 4Mar 4, 2022Lundbeck
NCT04884763Phase 2Nov 2, 2021Indiana University, Novartis, Regenstrief Institute
NCT05049057Phase 2Oct 31, 2021Henry M. Jackson Foundation for the Advancement of Military Medicine, Uniformed Services University of the Health Sciences
NCT04970355Phase 2Oct 28, 2021Humboldt University
NCT04920331Phase 1Sep 7, 2021Mayo Clinic
NCT04825678Phase 4Jun 28, 2021Amgen
NCT04465357Phase 4Oct 22, 2020Clinvest, Diamond Headache Clinic, Harvard University
NCT04674020Phase 4Oct 22, 2020University of Copenhagen
NCT04592952Phase 4Oct 8, 2020University of Copenhagen
NCT04603976Phase 4Sep 25, 2020University of Copenhagen
NCT04452929N/AJul 22, 2020Novartis, University of Copenhagen
NCT04252742Phase 4Jul 17, 2020Amgen
NCT04419259Phase 2Jun 30, 2020Novartis, University of Copenhagen
NCT04265755Phase 4Apr 19, 2020Amgen
NCT04249427Phase 4Mar 31, 2020Amgen, Duke University
NCT04294147Phase 4Mar 17, 2020Eli Lilly
NCT04303845Phase 2Mar 10, 2020Mayo Clinic
Showing 20 of 53 trials
Page 1 / 3

Organizations

Research & Development (24)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
AmgenFor profit282342012
NovartisFor profit13742017
University of CopenhagenAcademic/Hospital7732019
Mayo ClinicAcademic/Hospital4432019
Department of DefenseGovernment2012019
Harvard UniversityAcademic/Hospital2122020
University of MarylandAcademic/Hospital2212022
AllerganFor profit1112019
Arizona State UniversityAcademic/Hospital1012019
ClinvestFor profit1012020
Department of Veteran AffairsGovernment1012019
Diamond Headache ClinicAcademic/Hospital1112020
Duke UniversityAcademic/Hospital1112020
Eli LillyFor profit1112020
Henry M. Jackson Foundation for the Advancement of Military MedicineAcademic/Hospital1112021
Humboldt UniversityAcademic/Hospital1112021
Indiana UniversityAcademic/Hospital1112021
LundbeckFor profit1112022
RecordatiFor profit1012023
Regenstrief InstituteAcademic/Hospital1012021
24 organizations
Page 1 / 2

Marketing (2)

OrganizationOrg typeRelationshipDate
AmgenFor profitMKTGMay 17, 2018
AmgenFor profitNDAMay 17, 2018